Normal view
- MacMagazine
- Sylvia Hoeks se junta ao elenco de βDisavowedβ, futura sΓ©rie do Apple TV com James Marsden
Sylvia Hoeks se junta ao elenco de βDisavowedβ, futura sΓ©rie do Apple TV com James Marsden
O elenco de βDisavowedβ, vindouro thriller de aΓ§Γ£o do Apple TV, ganhou mais um nome de peso. Segundo o Deadline, a atriz Sylvia Hoeks β conhecida por seus papΓ©is em βParceiras no Crimeβ (βRide or Dieβ) e βSeeβ β Γ© a mais nova contratada como membro regular do elenco.
Detalhes sobre a personagem de Hoeks na trama ainda nΓ£o foram revelados.
Anunciada em maio, a sΓ©rie Γ© estrelada por James Marsden e jΓ‘ havia somado Norman Reedus ao time em agosto. Em βDisavowedβ, acompanharemos o lendΓ‘rio agente da CIA Brad Griffin (Marsden) logo apΓ³s ser demitido abruptamente no meio de uma caΓ§ada global a um assassino responsΓ‘vel pela morte de um colega. Marginalizado no mundo da inteligΓͺncia, o protagonista decide ir atrΓ‘s da recompensa de US$15 milhΓ΅es pelo assassino.
Hoeks Γ© reconhecida internacionalmente por seu papel como Luv em βBlade Runner 2049β e tambΓ©m esteve no elenco de βSeeβ, outra produΓ§Γ£o do Apple TV, como a Rainha Kane.
βDisavowedβ Γ© uma criaΓ§Γ£o original e o primeiro projeto televisivo da dupla formada por Art Marcum e Matt Holloway. Eles tambΓ©m serΓ£o produtores executivos ao lado de Marsden, Tom Spezialy, Michelle MacLaren e Rebecca Hobbs. MacLaren, de βThe Morning Showβ e βBreaking Badβ, dirigirΓ‘ os dois primeiros episΓ³dios.
A Blue Marble Pictures β responsΓ‘vel por βPachinkoβ β produzirΓ‘ a sΓ©rie em conjunto com o Apple Studios, com Theresa Kang e Caroline Garity tambΓ©m como produtoras executivas.
βDisavowedβ ainda nΓ£o possui uma data de estreia confirmada.
O AppleΒ TV estΓ‘ disponΓvel no aplicativo AppleΒ TV em mais de 100Β paΓses e regiΓ΅es, seja em iPhones, iPads, AppleΒ TVs, Macs, dispositivos Android, smart TVs ou online β alΓ©m de tambΓ©m estar em aparelhos como Roku, Amazon Fire TV, Chromecast com Google TV, consoles PlayStation e Xbox. O serviΓ§o custa R$34,90 por mΓͺs, com um perΓodo de teste gratuito de 7Β dias. Por tempo limitado, quem comprar e ativar um novo iPhone, iPad, AppleΒ TV ou Mac ganha 3Β meses do AppleΒ TV. Ele tambΓ©m faz parte do pacote de assinaturas da empresa,Β oΒ Apple One.
NOTA DE TRANSPARΓNCIA: O MacMagazine recebe uma pequena comissΓ£o sobre vendas concluΓdas por meio de links deste post, mas vocΓͺ, como consumidor, nΓ£o paga nada mais pelos produtos/serviΓ§os usando os nossos links de afiliado.


Norman Reedus joins James Marsden in Apple TV action thriller series βDisavowedβ
Norman Reedus is joining the series-regular cast of Apple TVβs upcoming action thriller βDisavowed.β
The project, created by Art Marcum and Matt Holloway (Iron Man, Uncharted), stars James Marsden as legendary CIA case officer Brad Griffin. Griffin is abruptly fired in the middle of a global hunt for an elusive assassin who killed his colleague. Disgraced and cut off from the intelligence world, he decides to pursue the $15 million federal bounty on the assassinβs head. Reedusβ character has not been revealed.
The series comes from Apple Studios. Marcum and Holloway executive produce alongside Tom Spezialy, Michelle MacLaren, Rebecca Hobbs, and Marsden. Blue Marble Pictures (Pachinko) produces, with Theresa Kang and Caroline Garity also serving as executive producers. MacLaren (The Morning Show, Breaking Bad) will direct the first two episodes and executive produce with Hobbs under her overall deal with Apple TV.
Reedus is best known for playing Daryl Dixon across 11 seasons of AMCβs The Walking Dead and the spinoff The Walking Dead: Daryl Dixon, which is set to conclude after its upcoming fourth season. He also starred as Murphy MacManus in The Boondock Saints and its sequel, and is in pre-production on a third installment as star and executive producer. Recent credits include Takashi Miikeβs untitled Kyoto project; he next appears in Mark Heymanβs Pendulum.
MacDailyNews Note: Apple TV is available on the Apple TV app in over 100 countries and regions, on over 1 billion screens, including iPhone, iPad, Apple TV 4K, Apple Vision Pro, Mac, popular smart TVs from Samsung, LG, Sony, VIZIO, TCL and others, Roku and Amazon Fire TV devices, Chromecast with Google TV, PlayStation and Xbox gaming consoles, and at tv.apple.com, for $12.99 per month with a seven-day free trial for new subscribers. For a limited time, customers who purchase and activate a new iPhone, iPad, Apple TV 4K or Mac can enjoy three months of Apple TV for free.
β
Please help support MacDailyNews β and enjoy subscriber-only articles, comments, chat, and more β by subscribing to our Substack: macdailynews.substack.com. Thank you!
Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.
The post Norman Reedus joins James Marsden in Apple TV action thriller series βDisavowedβ appeared first on MacDailyNews.
Which Families Pay Most for Neonatal Intensive Care? Analyzing NICU Out-of-Pocket Costs
The price of saving a newbornβs life can extend far beyond the hospital walls. A new analysis published in the Journal of Perinatology is drawing attention to a largely invisible consequence of neonatal intensive care: the direct medical out-of-pocket costs paid by families. The study, led by researchers Gorka, Profit and Phibbs, examines who carries the greatest financial burden during a neonatal intensive care unit admission and investigates how structural conditions may shape those costs.
Neonatal intensive care is among the most technologically advanced forms of medicine. Infants in NICUs may require mechanical ventilation, incubators that regulate temperature and humidity, continuous heart and oxygen monitoring, intravenous nutrition, specialized medications and repeated laboratory testing. These interventions can be lifesaving, particularly for babies born extremely prematurely or with serious medical complications. Yet the financial consequences of receiving this care are not experienced equally by every household, even when families receive treatment in the same health-care system.
The researchersβ focus is direct medical out-of-pocket spending: the money families must pay themselves for medical services connected to a NICU admission. This can include deductibles, copayments, coinsurance and other forms of cost sharing that remain after insurance has paid its portion. Unlike the total hospital charge or the amount reimbursed by an insurer, out-of-pocket cost reflects the portion that reaches a familyβs own budget. For households already coping with an unexpected high-risk birth, even relatively small individual charges can accumulate rapidly.
The study is designed not only to document these expenses, but also to explore the structural forces behind differences in cost burden. In health economics, structural contributions refer to the way institutions and systems distribute risk and resources. Insurance design, employment-linked coverage, household income, geographic location, hospital characteristics and access to public assistance can all affect how much a family ultimately pays. Two infants with similar clinical needs may therefore generate very different financial experiences for their parents, depending on the architecture of coverage surrounding them.
That distinction matters because the effects of a NICU admission are not limited to the newbornβs medical condition. Parents may need to travel long distances to reach a specialized hospital, arrange accommodation near the facility, pay for transportation or meals, and take unpaid leave from work. These expenses may not always appear in estimates of direct medical out-of-pocket costs, but they can intensify the economic shock associated with a prolonged admission. The medical bill is only one component of the broader financial strain that can accompany neonatal illness.
A central question raised by the analysis is whether the families with the fewest financial resources are also the ones most exposed to high cost sharing. A payment that is manageable for a high-income household may consume a substantial share of a lower-income familyβs monthly budget. Economists often describe this pattern as a disproportionate cost burden: the absolute amount paid may not be the highest, yet the payment represents a greater fraction of household resources. This distinction can reveal inequities that remain hidden when researchers look only at average dollar amounts.
The findings are expected to be relevant to health-policy debates about medical debt, insurance protection and the financial consequences of premature birth. If structural factors account for meaningful differences in family payments, reducing inequality may require more than improving clinical care. Potential responses could include limits on neonatal cost sharing, stronger protections against unexpected bills, expanded eligibility for public coverage and assistance with transportation or family support services. The analysis may also help hospitals and policymakers identify families at risk of financial hardship while an infant is still receiving care.
The issue has significance beyond individual hospitalizations because NICU care can influence a familyβs financial stability long after discharge. Parents may face follow-up appointments, medications, developmental assessments and specialist care for children who experienced complications of prematurity or serious illness. Medical expenses can overlap with reduced work hours, job loss or the need for one parent to become a full-time caregiver. A short period of intensive treatment can therefore produce a long economic aftershock, particularly when families lack savings or paid leave.
By placing family payments at the center of neonatal research, Gorka, Profit and Phibbs emphasize a dimension of NICU care that is often absent from clinical success measures. Survival, complications and length of stay remain essential indicators, but they do not fully describe the experience of families navigating intensive care. Understanding who pays the most, why they pay it and how those payments relate to broader social structures could help redefine quality in neonatal medicine. The studyβs message is potentially viral because it connects cutting-edge life-saving technology with a simple but consequential question: when medicine saves a baby, how much of the cost is left for the family to survive?
Subject of Research: Direct medical out-of-pocket costs of neonatal intensive care admissions and structural factors contributing to differences in financial burden among NICU families.
Article Title: Who pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families
Article References: Gorka, N., Profit, J. & Phibbs, C.S. βWho pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families.β Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02869-6
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02869-6
Keywords: neonatal intensive care, NICU, out-of-pocket costs, medical expenses, health-care inequality, premature birth, financial burden, insurance, neonatal health, health policy
- MacDailyNews
- James Marsden to star in Apple TV comedy βBad News Dadsβ from Stephen Falk and Berlanti Productions
James Marsden to star in Apple TV comedy βBad News Dadsβ from Stephen Falk and Berlanti Productions
According to an exclusive report from Deadlineβs Nellie Andreeva, Apple TV is developing βBad News Dads,β a half-hour comedy starring and executive produced by James Marsden. The project comes from βYouβre the Worstβ creator Stephen Falk, alongside Berlanti Productions and Warner Bros. Television, where Greg Berlanti holds an overall deal.
Based on the upcoming novel by Adam Frost, the series follows an inept menβs recreational baseball league. When one playerβs wife dies in a suspicious accident, friendship-starved Ben (played by Marsden) rallies two teammates for an often-misguided investigation into what they increasingly believe was murder. While the title and baseball setting nod to βThe Bad News Bears,β the story is an original concept with no direct connection to the classic sports film.
Falk, Marsden, and Frost executive produce with Greg Berlanti, Sarah Schechter, Leigh London Redman, and Robbie Rogers for Berlanti Productions. Frostβs novel is scheduled for publication on April 6, 2027, by Simon & Schuster/Atria/Emily Bestler Books.
The project continues Apple TVβs interest in mystery-comedy fare, a genre boosted by series like βThe Afterpartyβ and Huluβs βOnly Murders in the Building.β It also extends Marsdenβs recent work with the streamer: he recently appeared in βYour Friends & Neighborsβ and stars in and executive produces the upcoming action thriller βDisavowed.β Marsden, known for alternating between drama and comedy (with Emmy nominations for both βParadiseβ and βJury Dutyβ), next reprises Cyclops in βAvengers: Doomsday.β
Falk, whose other credits include Apple TVβs βHello Tomorrow!,β Netflixβs βOrange Is the New Black,β and Showtimeβs βWeeds,β also has a βHit Manβ series inspired by the Glen Powell film in development at Netflix. Berlanti Productions has multiple projects advancing elsewhere, including series at Amazon MGM Studios and Disney+.
β
MacDailyNews Note: Apple TV is available on the Apple TV app in over 100 countries and regions, on over 1 billion screens, including iPhone, iPad, Apple TV 4K, Apple Vision Pro, Mac, popular smart TVs from Samsung, LG, Sony, VIZIO, TCL and others, Roku and Amazon Fire TV devices, Chromecast with Google TV, PlayStation and Xbox gaming consoles, and at tv.apple.com, for $12.99 per month with a seven-day free trial for new subscribers. For a limited time, customers who purchase and activate a new iPhone, iPad, Apple TV 4K or Mac can enjoy three months of Apple TV for free.
β
Please help support MacDailyNews β and enjoy subscriber-only articles, comments, chat, and more β by subscribing to our Substack: macdailynews.substack.com. Thank you!
Support MacDailyNews at no extra cost to you by using this link to shop at Amazon.
The post James Marsden to star in Apple TV comedy βBad News Dadsβ from Stephen Falk and Berlanti Productions appeared first on MacDailyNews.
- NYT - Energy & Environment
- Trump Administration Is Undoing Plans to Boost Workplace Heat Protections
Trump Administration Is Undoing Plans to Boost Workplace Heat Protections

Β© Allison Joyce/Agence France-Presse β Getty Images
Trump Administration Is Undoing Plans to Boost Workplace Heat Protections
Why Restarting a Nuclear Power Plant Can Be Much Harder Than Expected

Dunes Sagebrush Lizard Stripped of Endangered Status by Judge
E.P.A. Moves to Loosen Limits on Pollution From Trucks

Β© Justin Sullivan/Getty Images
Dementia Projected to Cost the U.S. $818 Billion in 2024
A groundbreaking study led by researchers at the University of Southern California (USC) has revealed that Alzheimerβs disease and related dementias are projected to impose an astronomical economic burden on the United States in 2026, amounting to an estimated $818 billion. This figure eclipses prior estimates as it incorporates often overlooked and nuanced costs, including the significant toll on the quality of life for those living with dementia and the substantial unpaid care provided by family members and friends. This comprehensive accounting reshapes our understanding of dementiaβs societal impact, underscoring the urgency of policy innovation and resource allocation.
Traditional assessments of dementiaβs economic footprint have primarily focused on direct medical and long-term care expenses. However, this USC study breaks new ground by adopting a holistic approach that integrates broader social and economic dimensions. The model includes quality of life diminishment for patients and informal caregivers, loss of income due to both the disease and caregiving responsibilities, and the extensive, unpaid labor carried out by millions of family members β a demographic often in their prime working years. This multifaceted approach allows for a more accurate reflection of the real costs dementia inflicts on society.
The studyβs authors estimate that approximately 5.7 million Americans will be living with dementia in 2026, with 5.1 million of these individuals aged 65 and over. This demographic shift drives the increasing financial demands on healthcare systems and families alike. More crucially, the profound cognitive and functional decline experienced by dementia sufferers translates to a staggering $320 billion in lost quality of life, representing the single largest cost category. Care partners, often emotionally and physically strained, suffer quality-of-life costs valued at an additional $15 billion, quantifying the invisible burden that has been historically underestimated.
Unpaid caregiving, a cornerstone of dementia support, amounts to an astonishing 6.8 billion hours annually, contributed by approximately 5.2 million unpaid caregivers. This contribution is monetized at $237 billion, illustrating the massive economic value of informal care networks sustaining individuals with dementia. Long-term medical care, which includes nursing homes, home health services, and medical treatments, is projected at $222 billion. Medicare and Medicaid programs are shoulder approximately 70% of these costs, creating fiscal pressures on public health financing, while families and patients face out-of-pocket expenses near $46 billionβa significant financial stressor for many households.
Furthermore, the study incorporates lost wages, quantifying foregone earnings of $23 billion for both individuals living with dementia and their unpaid caregivers. These labor market impacts have wide-ranging implications for household financial stability and overall economic productivity. By deploying a dynamic microsimulation modeling framework and leveraging large nationally representative datasetsβsuch as the Health and Retirement Study and administrative data from Medicare and Medicaidβthe researchers have crafted a data-driven lens through which to forecast future dementia costs under various clinical and policy scenarios.
This evolving cost model is significant not only for its predictive power but for its potential to inform decision-making at multiple levels. It integrates peer-reviewed methodologies, published in a dedicated methods paper that ensures transparency in data sources, assumptions, and simulations. This methodological rigor equips policymakers, healthcare providers, and researchers with a robust platform to interrogate the efficacy of emerging treatments, changes in care delivery models, and evolving health policies. The goal is to better understand how these innovations might shift dementiaβs economic and social impact.
The USC-led teamβs interdisciplinary composition enhances the studyβs depth and applicability. Contributors hail from diverse academic units within USCβincluding the Price School of Public Policy, the Mann School of Pharmacy and Pharmaceutical Sciences, the Davis School of Gerontology, and the Viterbi School of Engineeringβas well as esteemed external collaborators from the Alzheimerβs Association and the University of Pennsylvania. This collaboration has generated a model enriched by real-world insights from people with mild cognitive impairment and their care partners, gathered through Alzheimerβs Association panels. Their lived experiences add critical context often absent from purely quantitative analyses.
In parallel with advances in medical science, this research dovetails with promising trends in dementia detection and management. FDA-approved blood tests now allow for the pre-symptomatic identification of Alzheimerβs pathology, while emerging therapeutics show potential in slowing disease progression. Innovative care models focused on keeping individuals at home for longer durations while supporting family caregivers further signal a paradigm shift in dementia care. This studyβs comprehensive cost framework can serve to evaluate the economic and societal ripple effects of such innovations, offering a valuable forecasting tool amid the rapidly changing landscape.
Lead researcher Julie Zissimopoulos emphasizes that accurate, comprehensive cost assessments are vital for allocation of resources in the face of a growing dementia population. This modeling approach allows for simulations that address critical questions, such as how slow-progressing treatments could improve quality of life or reduce nursing home demand, yielding insights needed for smarter, evidence-based policymaking. For example, understanding potential reductions in caregiving burden or shifts in out-of-pocket expenses can guide investment priorities across public health and social services sectors.
Moreover, the dynamic microsimulation approach employed by the study captures longitudinal impacts on individual trajectories, accounting for how health interventions at earlier disease stages might alter future care needs and economic costs. By continuously updating the model with new data inputs and methodological enhancements, the USC team ensures that their projections remain responsive to evolving clinical knowledge and demographic trends, positioning the cost estimates as authoritative inputs for strategic planning.
A particularly striking takeaway is the valuation of informal caregiving, which emphasizes the critical yet underappreciated role family and friends play in sustaining the dementia-affected population. The emotional, physical, and financial strain borne by these caregivers often goes unrecognized in policy dialogues. Quantifying these costs helps to illuminate the hidden layers of dementiaβs societal toll, strengthening the argument for supportive interventions, caregiver resources, and systemic reforms to alleviate their burden.
Dana Goldman, founding director of the USC Schaeffer Institute, highlights that understanding the expanding economic footprint of dementia is fundamental to harnessing the full potential of scientific and care innovations. As Alzheimerβs disease and related dementias continue to challenge health systems globally, this study outlines a crucial framework for evaluating the interplay between emerging therapeutics, care delivery, and economic sustainability. It advocates for data-driven policies that adapt to and capitalize on these transformative changes.
This comprehensive analysis of dementiaβs economic burden thus represents a critical step forward in the public health and policy arenas. Its nuanced incorporation of quality-of-life metrics, unpaid caregiving, lost earnings, and formal healthcare expenses paints a detailed portrait of the multifaceted costs dementia imposes. As American society confronts a rapidly aging population, these findings serve as a clarion call to address the broad spectrum of dementiaβs impact, ensuring informed strategies to mitigate its profound human and economic consequences.
Subject of Research: Economic Impact of Alzheimerβs Disease and Related Dementias
Article Title: The 2026 U.S. Cost of Dementia: A Comprehensive Model Accounting for Quality of Life and Informal Caregiving
News Publication Date: 24 June 2026
Web References: https://schaeffer.usc.edu/cost-of-dementia-model/; https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71480
References: Zissimopoulos, J., et al. (2026). Comprehensive cost modeling of Alzheimerβs disease and related dementias. Alzheimerβs & Dementia: The Journal of the Alzheimerβs Association, doi:10.1002/alz.71480
Image Credits: USC Schaeffer Center for Health Policy & Economics
Keywords: Dementia, Alzheimerβs disease, Economic burden, Quality of life, Informal caregiving, Health care costs, Lost wages, Policy modeling, Aging population, Health economics, Microsimulation
How Flocking Birds βDefyβ One of Physicsβ Most Fundamental Laws
Why Sweden Is Spending Millions to Ditch School iPads and Bring Back Books
Tensions Are Rising Among States That Rely on the Colorado River
Tensions Are Rising Among States That Rely on the Colorado River

Β© Nina Riggio for The New York Times
Democrats Once Vowed to Stop Oil and Gas. Now Theyβre Not So Sure.
Democrats Once Vowed to Stop Oil and Gas. Now Theyβre Not So Sure.

Β© Anna Moneymaker/Getty Images
I.R.A. Rebates for Appliance Swaps Could Be Phased Out

Β© Bing Guan for The New York Times
- NYT - Energy & Environment
- E.P.A. to Repeal Some Limits on βForever Chemicalsβ in Drinking Water
E.P.A. to Repeal Some Limits on βForever Chemicalsβ in Drinking Water

Β© Haiyun Jiang/The New York Times